Hitchin, UK, 1st December 2005 York Pharma, the AIM-listed (AIM:YRK) strategic acquirer, developer and marketer of pharmaceutical products in the field of dermatology, announces the appointment of a new Non-Executive Director, Dr. Allan Salem, who will join the Company with immediate effect.  

Dr Salem, 61, gained an MA., DPhil in Biochemistry and Microbiology at Wadham College, Oxford. Subsequently, he lectured in microbiology at the University of Sheffield, before joining May & Baker Limited in 1973 as a research scientist, where he rose to become a Senior Manager in the Pharmaceutical Division, before joining Ethypharm SA in 1987 as Regional Director. In 1990, he was appointed Senior Business Development Manager at Mundipharma International Limited and in 1998 joined Bioglan Pharma Plc as Pharmaceutical & Business Development Manager. Since 2002 Dr. Salem has operated as a pharmaceutical industry consultant for a number of International companies.  

Max Dyer Bartlett, Chairman of York Pharma, said “I am delighted Dr. Salem has agreed to join York Pharma as our business develops rapidly in all areas. His R & D expertise coupled with his International business development skills will be invaluable in helping to guide the board’s planning and decision making processes.” 

The following information regarding Allan Salem falls to be disclosed under paragraph g of Schedule Two of the AIM Rules for Companies. 

Current Directorships:

Greystead Properties Limited

Eastern Suburbs Estates Limited 

There are no details that require to be disclosed under paragraph (g) (iii) to (viii) of Schedule Two of the AIM Rules for Companies. 

--ENDS-- 

For more information please contact: 

York Pharma plc	Tel: +44 (0) 870 066 4453
Terry Sadler, Chief Executive Officer

Northbank Communications	Tel: +44 (0) 207 886 8150
Emma Palmer (financial enquiries) Rowan Minnion (media enquiries)

 

Notes to editors: 

About York Pharma plc

York Pharma is an AIM-listed strategic acquirer, developer and marketer of pharmaceutical products in the field of dermatology. Its portfolio now embraces skin diseases that make up more than 70% of the global $10bn dermatology market, and its lead product, Abasol for the treatment of fungal infections of the skin, has been filed for European marketing approval. For further information, please go to www.yorkpharma.com